Company profile: Microarrays
1.1 - Company Overview
Company description
- Provider of microarray platforms and services for analyte testing, diagnostics, and personalized medicine, including pathway-focused gene expression arrays (MI PathArray), whole-genome microarrays (MI ReadyArray), DNA and protein/antibody arrays, assay development, and lab services for RNA profiling and microarray assays.
Products and services
- Assay Development: Custom-engineered services that create, validate, and fabricate microarray-based assays for analyte testing, diagnostics, and personalized medicine across diverse applications using validated workflows
- MI PathArray: Pathway-specific microarray platform focusing on inflammation, cancer, and apoptosis, enabling targeted gene expression analysis of defined signaling networks for precise pathway-level research interrogation
- MI ReadyArray: Research-grade whole-genome microarrays delivering extensive gene expression coverage across various organisms, enabling comprehensive transcriptome profiling for broad comparative studies.
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Microarrays
Spindiag
HQ: Germany
Website
- Description: Provider of an easy-to-use, compact, automated point-of-care PCR system for broad, fast, and affordable pathogen detection. The Rhonda player with Rhonda disks detects infectious agents—including SARS-CoV-2, Influenza A/B, RSV, and MRSA—with results in under one hour; the SARS-CoV-2 disk supports direct swab insertion. The Rhonda app displays results for mobile use, and test outcomes can be transferred directly into patient records.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Spindiag company profile →
Axxam
HQ: Italy
Website
- Description: Provider of integrated drug discovery services from target validation to lead generation, including assay development, high-throughput screening and hit-to-lead profiling, with a focus on small-molecule drugs targeting inflammation. Offers RNA biology platforms, SARS-CoV-2 cell-based and biochemical assays, a 349k-compound AXXDiversity library, and the AXXSense platform for flavors, fragrances and taste modulation.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Axxam company profile →
Synlab
HQ: Germany
Website
- Description: Provider of laboratory diagnostics for human and veterinary medicine and environmental analysis services. Delivers wide-ranging laboratory testing, specialty and genetic testing (including preimplantation), supported by 2,000+ medical experts across 30+ countries and 2,000+ blood collection points. Also focuses on medical supplies trade, clinical trials, and consulting.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Synlab company profile →
Centogene
HQ: Germany
Website
- Description: Provider of methods and technology for human genetics analysis, delivering genetic diagnostic analyses of rare inherited diseases and transforming global genetic data into medical decisions to create broader awareness for patients of all ethnicities around the world.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Centogene company profile →
NAT Diagnostics
HQ: United States
Website
- Description: Provider of a molecular diagnostic platform for true point-of-care infectious disease testing in physician offices, clinics, pharmacies, and other sites where patients are seen by medical personnel, delivering highly accurate results to improve the diagnostic experience.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full NAT Diagnostics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Microarrays
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Microarrays
2.2 - Growth funds investing in similar companies to Microarrays
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Microarrays
4.2 - Public trading comparable groups for Microarrays
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →